Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. van der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Pieter-Jan van Dam, Diana Stanoeva, Sofie DaelemansSanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano

Research output: Contribution to journalComment/Letter to the editorAcademic


In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.
Original languageEnglish
JournalNature medicine
Early online date2023
Publication statusE-pub ahead of print - 2023

Cite this